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Abstract
Every day, patients with dementia, their families, and their physicians face 
the enormous challenges of this pervasive life-changing condition. Seeking 
help, often grasping at straws, victims, and their care providers are confronted 
with misinformation and myths when they search the internet or other sources. 
When Persons with Dementia (PWD) and their caregivers believe and/or act 
on false information, proper treatment may be delayed, and ultimately damage 
can be done. In this paper, we review commonly misunderstood issues 
encountered in caring for PWD. Our goal is to equip Primary Care 
Practitioners (PCPs) with accurate information to share with patients and 
families, to improve the outcomes of PWD to the greatest extent possible. 
While there are innumerable myths about dementia and its causes and 
treatments, we are going to focus on the most common false claims or 
misunderstandings which we hear in our Internal Medicine practice at 
Marshall Health. We offer suggestions for busy practitioners approaching 
some of the more common issues with patients and families in a clinic setting. 
Introduction
The numbers are now familiar but remain staggering – 5.3 million 
Americans have Alzheimer’s disease, and around 36,000 of them are 
in West Virginia. Within 10 years, those numbers are going to increase 
to 7 million and 44,000.1 Clearly, every PCP has PWD on his or her 
patient panel. Recent data analysis shows that documented diagnosis 
of Alzheimer’s disease in rural counties is substantially (11%) lower 
than in urban counties, so in West Virginia and other rural states, it is 
likely that each PCP has even more such patients than they realize.2 
While it is extremely important that all parties have adequate 
knowledge of the disease process, and potential sources of 
information are widely available, these sources can include some 
gross misinformation. The internet, TV, and second-hand reports 
of “what John’s doctor told him” can influence families to make bad 
decisions and in other ways lead to poor care. PCPs, therefore, need 
to be ready with accurate information to share during office visits. 
It is universally true that PCPs are pressed for time, and do not have 
the luxury of either extensive literature reviews or long educational 
sessions with their patients and families. We identify the more common 
and egregious myths about Alzheimer’s and other dementias and 
offer suggestions for efficient and effective ways to debunk them. 
Myths vs. Clinical Truths for PWD
Myth I: “My mother had it, my grandmother had it. I’m doomed.”
The Truth: There is a genetic component to Alzheimer’s disease 
and other dementias. Risk-conferring mutations which may or may 
not eventually cause disease are rather common, but determinative 
genetic mutations which inevitably lead to the disorder are quite rare.
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While age remains the greatest risk factor for 
dementia, family history is significant. Having a 
single first-degree relative with dementia increases 
an individual’s risk by 10 to 30 percent3, although 
the excess risk is less if the affected family 
member was older than 85. Recent advances in 
medical genomics offer great promise in terms 
of risk quantification. However, most of this 
information are still unevaluated “big data”. 
Certain scenarios are clearer than others. 
Young-onset Alzheimer’s dementia, with initial 
symptoms between the ages of 30 and 60, has 
been extensively characterized in terms of genetic 
loci involved. Family history is quite relevant in 
such cases, as the disease in most young-onset 
cases follows an autosomal dominant pattern with 
high penetrance. For most other patients, however, 
the development of dementia depends on multiple 
risk factors, of which family history is only one. 
Family history of late-onset Alzheimer’s is a risk 
factor for the development of dementia. However, 
hypertension, diabetes, hyperlipidemia, physical 
inactivity, depression, obesity, and smoking are also 
risks. Some evidence suggests that up to a third 
of cases of Alzheimer’s disease are attributable to 
these factors 4. Risk factor modification (particularly 
in middle adulthood) may be key in dementia risk 
mitigation; seemingly mundane education in primary 
prevention could eventually yield substantial benefits. 
In many cases, patients and families ask for 
expensive genetic tests to gauge or decrease 
risk. Two points should be emphasized: 
• First, family history of dementia does not mean 
an individual is going to develop dementia. 
• Second, lack of family history does not guarantee 
that a person is going to escape dementia. 
It may be worth specifically pointing out to families 
who request testing - with currently available genetic 
testing, one can only confirm what one already 
knows, that is, whether one is at higher risk or not. If a 
person is a member of one of the rare families with a 
known determinative mutation, testing can confirm the 
presence or absence of the gene in a given individual, 
but again these are rare cases, and counseling must 
be available to those who choose to be tested. 
Myth II: “I’ve lost my keys again, 
I need Aricept™!”
Truth: Memory lapses, such as losing your 
keys, forgetting someone’s name, or forgetting 
why you entered a room are common with normal 
aging. They do not imply dementia nor predict it. 
By definition, dementia is a significant decline in 
cognition that interferes with one’s ability to carry out 
normal daily functions. Subjective memory complaints 
rarely correlate to dementia. Once a patient becomes 
concerned about their memory, the PCP needs to 
be efficiently prepared to decide if there is a real 
concern or if the patient is in fact quite normal.1 
An effective first step toward validating a patient’s 
worry about their subjective memory concerns 
is to discern if the memory lapses have caused 
interference with their daily activities.5 Practical 
differentiation can be made along these lines: 
Drug or Alcohol Problem? Mental Illness?
If you have a drug or alcohol problem, or are suffering from a mental illness you can get help by 
contacting the West Virginia Medical Professionals Health Program. Information about a practitioner’s 
parti­cipation­in­the­program­is­confidential.­Prac­titioners­entering­the­program­as­self-referrals­without­
a­complaint­filed­against­them­are­not­reported­to­their­licensing­board.
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• A normal memory lapse might be forgetting 
the name of someone whom you met 
only once or twice, or forgetting why 
you went into a particular room.
• Mild cognitive impairment is forgetting the name 
of someone you see daily and not remembering 
it later. Mild cognitive impairment (MCI) (now 
known as Neurocognitive Disorder- Minor) 
does not significantly interfere with daily 
activities. It has more symptoms and disability 
than normal forgetfulness; it is described as 
the patient and the examiner both knowing 
that something is different or wrong, but still 
the patient can carry on with his normal life. 
• In the case of actual dementia (Neurocognitive 
Disorder – Major), affected persons may not 
complain of memory loss but indeed may deny 
that they have any symptoms.6 Observers 
can tell that these individuals have cognitive 
problems, which can be manifested by not just 
forgetting names, but forgetting the function 
of common objects and getting lost. 
Patients worry about such memory lapses, 
not because they interfere with their activities, 
Figure 1. Illustration of “dementia” as the general term encompassing memory loss disorders of various 
etiologies.
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but because they fear they are going to develop 
dementia, but there appears to be no link between 
normal forgetfulness and the development of MCI 
or dementia. MCI, on the other hand, may progress; 
on average, 10% per year of persons identified 
with MCI may progress to a diagnosis of actual 
dementia. The medications we currently have 
available for dementia are not useful for normal 
forgetfulness nor MCI though trials are underway to 
assess the benefits of treating minimal impairment. 
Myth III: “Well, if it’s Alzheimer’s, at least, 
it’s not dementia.” and “So if it’s dementia 
now, when will it go into Alzheimer’s?”
The Truth: While they are obviously related, 
Alzheimer’s disease is not a stage of dementia, 
nor is dementia a stage of Alzheimer’s.
People have usually been trying to research 
the possible diagnoses by the time they present 
for evaluation; this can lead to major confusion 
for those with insufficient background knowledge. 
The two most common misunderstandings 
are 1) that AD and dementia are two separate 
and distinct disorders, or 2) that Alzheimer’s is 
an early stage of dementia or vice versa. 
PCPs should explain that “Dementia” is the 
umbrella term for chronic cognitive impairment 
disorders, and that Alzheimer’s is only one type 
of dementia. It may be useful to demonstrate 
the concept with a diagram such as Fig. 1. 
Alternatively the analogy “All dogs are four-legged 
animals but all four-legged animals aren’t dogs” 
may be used. Understanding the relationship 
between these terms helps considerably in 
future attempts to learn about the disease. 
 
Myth IV: “The scan showed it 
was Alzheimer’s disease.”
The Truth: At this point, no scan, no lab test, 
and no examination can unequivocally confirm 
a specific etiology of dementia in most cases.
Extensive research is bringing us closer to 
the day when a premortem test can definitively 
diagnose Alzheimer’s and other etiologies 
of dementia. However, it is a disservice to 
patients and families to imply to them that 
anything more than a probable diagnosis can 
be made currently in the majority of cases. 
The National Institute on Aging – Alzheimer’s 
Association workgroup published updated diagnostic 
criteria in 2011, the first significant revision since 
1984.7 They begin with core clinical criteria for the 
diagnosis of all-cause dementia. Once a patient 
meets these basic standards and is considered 
to have a diagnosis of dementia, further criteria 
are described for classifying diagnoses of 1) 
Probable Alzheimer’s dementia, 2) Possible AD 
dementia, and 3) Probable or possible AD dementia 
with evidence of AD pathology. These criteria 
explicitly state that the latter category is intended 
for research purposes only; the reason being that 
neither imaging nor lab studies which can produce 
“evidence of AD pathology” are specific, sensitive, 
or reliable enough to be used in clinical practice.
A brain imaging study is recommended in the 
workup of a patient with memory impairment, even 
though it is not diagnostic. CT scans are useful 
for ruling out conditions which may not have been 
suspected or which cannot be proven by examination 
alone, for example, small or symmetrical subdural 
hematomas or even tumors. Normal Pressure 
Hydrocephalus may sometimes be diagnosed with 
CT scanning. MRI of the brain can be helpful to 
document the extent of vascular disease or the 
disproportionate atrophy seen in different areas with 
various dementias. PET scanning with either of two 
agents can be very supportive of an AD diagnosis. 
With the “Pittsburgh Compound” marker, amyloid 
deposition can be seen, and with fluorodeoxyglucose 
(FDG)-PETs, loss of glucose uptake in damaged 
neurons is seen. However, because amyloid can be 
seen in PET scans long before clinical symptoms 
occur, and because quantitative analysis of FDG-
PET results is not standardized, these imaging 
studies cannot yet be considered diagnostic. 
Biomarkers, such as CSF levels of tau protein and 
Beta-amyloid, are also insufficiently standardized to 
be used clinically for confirmation of diagnosis. (Low 
CSF Aβ42, or elevated CSF total tau or phosphorylated 
tau, are positive markers of probable Alzheimer’s.) 
In addition to the lack of standardization, there is 
limited access to this testing in most community 
settings. At this time, these tests are an option for 
clinicians but are used only in clinical trials. Carefully 
applied clinical criteria are sufficient for diagnosis in 
most cases without the expense of biomarker testing 
or the potential problems of lumbar puncture.7
Myth V: “I told her over and over that her 
dad has been dead for 30 years and is not 
coming to get her. However, she still asked 
me the same question a hundred times.”
The Truth: Repetitiveness, and believing 
that people from the past are still present, 
are among the most common manifestations 
of Alzheimer’s and other dementias. These 
behaviors and beliefs cannot be corrected.
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Caregivers of PWD must deal with a number 
of disturbing symptoms. Which of the myriad 
behavioral and psychological symptoms of dementia 
can occur in a given person cannot be predicted, 
but some are more common than others. These 
include repetitiveness, loss of memory of current 
relationships with reversion to the belief that one’s 
parents and siblings are as they were in the person’s 
childhood, excess agitation over small matters, and 
losing/hiding items but believing they were stolen. 
The main thing that caregivers need to know is 
that these behaviors are not volitional, and they 
should not argue with the patient. The PWD is not 
deliberately being difficult; rather, due to their brain 
damage, they are “existing in a different reality” at that 
moment. Arguing or trying to convince them otherwise 
may only escalate the agitation. Asking for a long 
dead person is particularly sensitive. No matter how 
many times they are told, they will not “learn” that 
the person is gone, and being so informed over and 
over can actually induce new grieving each time. 
A full review of communication techniques and 
behavioral treatment is beyond the scope of this 
paper. However, PCPs should be prepared to 
teach caregivers that the PWD cannot make new 
memories, and therefore “reality orientation” is 
not going to work. Diversion and non-committal 
responses to repeated questions (even frankly bizarre 
statements), may calm the person for at least a while, 
whereas arguing, scolding or loss of temper serves 
Entity Mechanism of Action Evidence
Acetyl-l-carnitine Lipid metab.; membrane structure; 
potent direct cholinergic agonist
2 large trials and Cochrane meta-analysis of 16 studies: 
No benefit
Ashwagandha (winter 
cherry; Indian ginseng)
Evergreen herb; antioxidant Indian traditional medicine; limited animal studies; 
possible benefit for anxiety: No benefit shown for 
dementia
Caprylic acid (Ketasyn™, 
Axona™); Coconut oil
Triglyceride from coconut or palm 
kernel oil –“alternative energy 
source for brain cells”
Testimonials; Phase II trial – no effectiveness; No 
Phase III trials done: Alz. Assoc. – not enough 
evidence to assess possible benefit as medical food
Co-Enzyme Q 10, 
Ubiquinone
Antioxidant Small trial of synthetic version: Not effective
Coral Calcium Calcium carbonate plus trace 
minerals
FDA and FTC filed complaints against the product for 
exaggerated claims
Curcumin Turmeric derivative; Anti-
inflammatory; Antioxidant
Traditional Indian spice: No clinical trials
Gingko Biloba Antioxidant; Anti-inflammatory Traditional Chinese medicine; Small trials and meta-
analysis in 199’s and 2000’s suggested benefit: Phase 
III trial – no benefit, and GEM (Gingko Evaluation and 
Memory trial) – no benefit
Huperzine A Properties similar to cholinesterase 
inhibitors
Traditional Chinese medicine (moss extract); Small trials 
ongoing: Alz. Disease Coop. Study (ADCS)- no benefit 
over placebo
Lecithin Choline phospholipid Several trials: No benefit
Nicotinamide Water soluble B vitamin No evidence of benefit
Omega-3 fatty acids DHA is chief Omega-3 in brain; 
Anti-inflammatory; Decrease risk of 
heart disease
FDA – Supportive but not conclusive evidence for DHA 
reducing risk of CAD: Trials inconclusive, marginal 
benefit in dementia
Periwinkle (vinpocetine) Possible vasoactive and 
neuroprotective 
Folk remedy in various areas of the world; Cochrane 
analysis: Inconclusive and does not support use
Phosphatidylserine Stabilizes neuron membranes FDA: Little scientific evidence to support claim of 
reduced dementia risk
Piracetam GABA derivative One well designed study and Cochrane analysis: No 
benefit
Tramiprosate 
(Alzhemed™, Vivimed™)
Modified amino acid taurine FDA: No benefit in Phase III trial
Table 1. Complementary and Alternative Medicine Agents Promoted for Use in Dementia
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no purpose. As long as the behavior is not overtly 
dangerous, the PWD need not be “corrected”. 
Myth VI: “I saw on Facebook that we need to 
give her coconut oil. It cured all those people.”
The Truth: As for all disorders in the age of 
the internet, Google is full of postings about 
complementary, alternative, herbal, and homegrown 
remedies for dementia. There is no significant 
scientific evidence to support the use of any of them. 
Complementary or Alternative Medicine (CAM) 
is a conundrum for practitioners. Often CAM is 
viewed by practitioners as not conforming to the 
mainstream of medical thought and practice, 
but there has been progress in understanding a 
proper place for CAM in our practices. Also, further 
credence for proper placement of these agents in 
our treatment plans is developing as we learn about 
mechanisms of action and potential clinical effects. 
However, like so many fashionable ideas, much 
hope has not defined clear benefit. Testimonials 
and traditional practices do not constitute scientific 
evidence upon which clear recommendations of 
benefit or cost-benefit can be defined. Billions of 
dollars per year are spent on CAM treatments in the 
hope of benefit for patients suffering from dementia. 
Families and patients must recognize that there is no 
regulation or standardization applied to supplements 
or “medical foods” by governing organizations 
such as FDA. This absence of regulation and 
oversight allows for propagation of unproven 
claims of effectiveness and safety, and for unclear 
parameters of purity. Additionally, there is a possibility 
of potential direct harm, such as interactions with 
prescribed medications. CAM, therefore, must be 
acknowledged to be occasionally safe, but sometimes 
to lead to harm to the unsuspecting patient, all 
with no accurate data regarding effectiveness. 
The impact of dementia is profound for the patient 
and family, so it is completely understandable that 
all options for possible benefit will be explored 
and even entertained. While there is a growing 
number of complementary, alternative, herbal, folk, 
supplemental remedies or “medical foods” which 
lay claim to benefiting our patients, none of these 
unregulated or non-standardized agents hold clearly 
documented evidence-based benefit for our patients. 
While hope abounds, there are no agents today with 
proven efficacy in dementia. Table 1 lists several 
agents which are commonly promoted as useful 
CAM agents for dementia8, along with the most 
recent assessment of their degree of effectiveness. 
Summary
Caring for people with dementia is an integral part 
of the role of a primary care provider. As difficult 
as it is to define and treat the disorders, we all 
strive to do it well. Caregivers are searching for 
knowledge, but frequently encounter poor information 
and erroneous assumptions. This paper offers 
a review of common situations in which families 
and patients may have been misled or may have 
drawn incorrect conclusions from confusing data. 
By being prepared to address quickly questions or 
statements, PCPs can go a long way toward getting 
all the participants in the care of PWD to speak the 
same language, which in turn can decrease errors, 
increase patient safety, and raise understanding of 
what still needs to be addressed through research.
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